Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.
Deal Watch: FTC Keeps Current Merger Guidelines In Place, For Now
Plus deals involving Incyte/Genesis, Merck & Co./Epitopea, Merck Serono/Asceneuron, Tivic Health/Statera and more.
More from Deal Watch
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
• By
Plus deals involving Hyundai/Pharma/Avelos, Yuhan/Boehringer Ingelheim, SciClone/Eisai, Viatris/Nxera/Idorsia, Nxera/Holling and Takeda/BridGene.
• By
Vertex, Sanofi, Hansoh and BMS/Myokardia have also recently exited deals. Callio launched with ADC technology from Hummingbird, plus more deals and tech transfer.
More from Legal & IP
• By
With Chair Lina Khan expected to exit the commission, the incoming administration may consider elevating one of the Republican commissioners on the panel to succeed her, at least on an acting basis.
• By
The exact causes leading to Chinese authorities’ investigation of the UK major remain unclear at this point, but its key oncology drugs are facing fierce local competition from homegrown rivals.
• By
The payout will bring GSK closer to resolving lawsuits which have occupied it for years – though investors are now likely to focus on new product growth concerns at the UK firm.